Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsNeighborhood Health RI Sephience Prior Auth | Open…
    Ask Trek AI about this page
    CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

    Sephience (sepiapterin) for phenylketonuria

    Customize your policy alerts

    Sign up for all Neighborhood Health Plan of Rhode Island policy alerts

    Know when Neighborhood Health Plan of Rhode Island releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Sephience (sepiapterin) to treat hyperphenylalaninemia in adult and pediatric members at least 1 month old with sepiapterin-responsive phenylketonuria when clinical, laboratory, dietary, dosing, and prior-treatment criteria are met.

    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicySephience (sepiapterin) for phenylketonuria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of specialist involvement, qualifying phenylalanine levels, renal status, diet, dosing, and inadequate response or intolerance to formulary sapropterin.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥1 monthMinimum member age
    ≥600 μmol/L ×2Historical Phe
    ≥360 μmol/LBaseline Phe
    60 mg/kgMaximum dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2 months
    Initial authorization
    6 monthsRenewal authorization

    Coverage Criteria and Exclusions

    Initial Therapy Criteria

    Covered for an initial 2-month authorization when all of the following criteria are met:

    Initial therapy criteria

    • Prescriber qualification: Prescribed by, or in consultation with, a physician who specializes in the treatment of metabolic disease and/or phenylketonuria (PKU).
    • Minimum age: Member is one month of age or older.≥1 month
    • Diagnosis and laboratory criteria

      • Historical phenylalanine measurements: Member has a clinical diagnosis of hyperphenylalaninemia (HPA) with documentation of a past medical history of at least 2 blood phenylalanine measurements greater than or equal to 600 μmol/L.≥2 measurements ≥600 μmol/L
      • Baseline phenylalanine level before starting treatment with the requested medication is greater than or equal to 360 μmol/L.≥360 μmol/L
    • Primary BH4 deficiency exclusion: Member has not been diagnosed with hyperphenylalaninemia due to pathogenic variants in GCH1, PTS, QDPR, SPR, or PCBD1, consistent with a diagnosis of primary BH4 deficiency.
    • Renal status: Documentation shows no abnormal physical examination or laboratory findings indicative of renal disease, including calculated GFR below 60 mL/min/1.73 m².GFR ≥60 mL/min/1.73 m²
    • Dietary therapy: The requested medication will be used in conjunction with a phenylalanine-restricted diet.
    • No prohibited combination therapy: The requested medication will not be used in combination with sapropterin products or Palynziq (pegvaliase-pqpz).
    • Weight documentation: The member’s most recent weight is documented.
    • Dose: The medication is prescribed at the appropriate FDA-approved dose based on the member’s weight and the dose does not exceed 60 mg/kg.≤60 mg/kg
    • Prior sapropterin response: Member has a documented inadequate treatment response or intolerance to a formulary sapropterin product.Inadequate response: blood Phe ≥360 μmol/L despite consistent use with dietary Phe restriction

    Continuation Therapy Criteria

    Covered for a 6-month renewal when the member continues to meet all initial criteria and at least one qualifying response criterion is met:

    Continuation therapy criteria

    • Continued initial eligibility: Member continues to meet all initial criteria.
    • Qualifying treatment response

      • Phenylalanine reduction: Achievement or maintenance of a 30% decrease in phenylalanine levels from baseline.30% decrease
      • Acceptable phenylalanine level: Phenylalanine levels are in an acceptable range.<360 μmol/L

    Coverage excludes members whose hyperphenylalaninemia is caused by pathogenic variants in GCH1, PTS, QDPR, SPR, or PCBD1, consistent with a diagnosis of primary BH4 deficiency.

    Sephience must not be used concurrently with sapropterin products—including sapropterin, Javygtor, or Kuvan—or with Palynziq (pegvaliase-pqpz).

    Coverage excludes members with abnormal physical examination or laboratory findings indicative of renal disease, including a calculated GFR below 60 mL/min/1.73 m².

    Indications other than treatment of hyperphenylalaninemia in adult or pediatric members at least 1 month old with sepiapterin-responsive phenylketonuria are considered experimental/investigational and not medically necessary.

    Clinical Thresholds and Limits

    Historical blood phenylalanine measurements
    Historical measurementsAt least 2 blood phenylalanine measurements ≥600 μmol/L
    Clinical contextMeasurements must support a clinical diagnosis of hyperphenylalaninemia
    DocumentationPast medical history documentation is required
    Baseline phenylalanine
    Baseline phenylalanine≥360 μmol/L
    TimingMeasured before starting the requested medication
    DocumentationBaseline level must be documented

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization — 2 Months

    Prior authorization for Sephience may be granted for 2 months when the member meets all initial PKU criteria, including the FDA-approved indication, specialist involvement, age, diagnosis, laboratory history, treatment requirements, and dosing requirements.

    • Member is at least 1 month of age and has sepiapterin-responsive phenylketonuria (PKU) with hyperphenylalaninemia (HPA).
    • Treatment is used with a phenylalanine (Phe)-restricted diet and is prescribed by, or in consultation with, a physician specializing in metabolic disease and/or PKU.
    • The member has at least 2 historical blood Phe measurements ≥600 μmol/L and a baseline Phe level ≥360 μmol/L before starting the requested medication.
    • The requested dose is the FDA-approved weight-based dose and does not exceed 60 mg/kg.
    Prior Authorization

    Continuation Authorization — 6 Months

    Renewal authorization may be granted for 6 months when the member continues to meet all initial criteria and the medical record demonstrates treatment response.

    Policy Background

    Sephience (sepiapterin) is covered for the treatment of hyperphenylalaninemia in adult and pediatric members 1 month of age and older who have sepiapterin-responsive phenylketonuria. Treatment must be used with a phenylalanine-restricted diet and is subject to documentation of qualifying phenylalanine levels, exclusion of primary BH4 deficiency and significant renal disease, and prior inadequate response or intolerance to a formulary sapropterin product.

    Key Definitions

    Hyperphenylalaninemia (HPA)
    DefinitionHyperphenylalaninemia is an elevated blood phenylalanine state
    Policy populationMembers with phenylketonuria who are at least 1 month of age
    Covered conditionSephiapterin-responsive phenylketonuria treated with a phenylalanine-restricted diet
    Inadequate treatment response
    Inadequate responseBlood phenylalanine remains ≥360 μmol/L
    Prior treatmentResponse is assessed despite consistent use of a formulary sapropterin product
    Dietary therapy

    Initial PKU Therapy

    Initial PKU Therapy Criteria

    Initial coverage for 2 months requires all of the following PKU criteria:

    Initial PKU therapy

    • Specialist prescriber: Prescribed by, or in consultation with, a physician who specializes in the treatment of metabolic disease and/or phenylketonuria (PKU).
    • Age: Member is one month of age or older.≥1 month
    • PKU diagnosis and laboratory confirmation

      • Historical HPA measurements: Member has a clinical diagnosis of hyperphenylalaninemia with at least 2 historical blood phenylalanine measurements greater than or equal to 600 μmol/L.

    PKU Renewal

    PKU Renewal Criteria

    Renewal coverage for 6 months requires continued fulfillment of all initial criteria and at least one qualifying response:

    PKU renewal

    • Continued initial criteria: Member continues to meet all initial criteria.
    • Qualifying response

      • Phenylalanine response: Achievement or maintenance of a 30% decrease in phenylalanine levels from baseline.30% decrease from baseline
      • Phenylalanine levels are in an acceptable range.<360 μmol/L

    Required Prior Treatment

    StepRequirementInadequate response or intolerance
    1Documented inadequate treatment response or intolerance to a formulary sapropterin product before Sephience coverage.Blood phenylalanine ≥360 μmol/L despite consistent use with dietary phenylalanine restriction, or intolerance to the product.

    Dose Limit

    Sephience (sepiapterin)
    DrugSephience (sepiapterin)
    Maximum doseDose must not exceed 60 mg/kg
    Dosing basisDose is based on the member’s weight and must be within the FDA-approved dose
    Policy Summary
    PayerNeighborhood Health Plan of Rhode Island
    PolicySephience (sepiapterin) for phenylketonuria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateFeb 1, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation of specialist involvement, qualifying phenylalanine levels, renal status, diet, dosing, and inadequate response or intolerance to formulary sapropterin.
    SourceLink
    On This Page
    Coverage Criteria and ExclusionsClinical Thresholds and LimitsAuthorization and Documentation RequirementsPolicy BackgroundKey DefinitionsInitial PKU TherapyPKU RenewalRequired Prior TreatmentDose Limit
  1. Neuropsychiatric improvement: Improvement in neuropsychiatric symptoms is documented.
  2. Renal function
    Calculated GFRMust not be below 60 mL/min/1.73 m²
    Renal statusNo abnormal physical examination or laboratory findings indicative of renal disease
    Coverage impactCalculated GFR below 60 mL/min/1.73 m² is an exclusion
    Maximum dose
    Maximum doseDose must not exceed 60 mg/kg
    Dosing basisDose must be based on the member’s weight
    Prescribing requirementDose must be within the appropriate FDA-approved dose
    Continuation phenylalanine response
    Phenylalanine responsePhenylalanine level below 360 μmol/L
    Authorization phaseUsed for 6-month continuation authorization
    DocumentationChart notes or medical records must demonstrate the acceptable phenylalanine level
    Continuation biochemical response
    Biochemical response30% decrease in phenylalanine levels from baseline
    Continuation requirementAchievement or maintenance of the 30% decrease qualifies as a response outcome
    DocumentationChart notes or medical records must demonstrate the decrease
    • Chart notes or medical records must show at least one of the following: a 30% decrease in Phe levels from baseline; Phe levels in an acceptable range (<360 μmol/L); or improvement in neuropsychiatric symptoms.
    • Continued authorization requires ongoing use with a Phe-restricted diet and continued compliance with all applicable exclusions and dosing requirements.
    Step Therapy

    Formulary Sapropterin Trial Required

    A documented inadequate response or intolerance to a formulary sapropterin product is required before authorization. Inadequate response means a blood Phe level ≥360 μmol/L despite consistent sapropterin use with dietary Phe restriction.

    • Submit the formulary sapropterin product name, treatment dates, and response information.
    • For intolerance, document the adverse effects, dates, severity, and outcome after discontinuation or attempted management.
    Documentation Required

    Required Clinical Documentation

    Submit clinical documentation supporting every authorization criterion, including specialist involvement, diagnosis, age, laboratory history, treatment history, and the requested regimen.

    • Specialist consultation or prescription by a physician who treats metabolic disease and/or PKU.
    • Member age and confirmed PKU diagnosis with sepiapterin-responsive HPA.
    • At least 2 historical blood Phe measurements ≥600 μmol/L and the pretreatment baseline Phe measurement ≥360 μmol/L.
    • Most recent member weight, requested weight-based dose, and confirmation that the dose does not exceed 60 mg/kg.
    • Documentation of a Phe-restricted diet and the required formulary sapropterin trial, including inadequate response or intolerance.
    • For renewal, chart notes or medical records documenting the qualifying Phe reduction, acceptable Phe level, or improvement in neuropsychiatric symptoms.

    Unsupported block type: denial_risk

    Denial Risk

    Clinical and Treatment Exclusions

    Authorization will be denied when clinical or treatment exclusions apply, including primary BH4 deficiency, renal disease, prohibited concurrent therapy, or failure to meet required treatment conditions.

    • The HPA is due to pathogenic variants in GCH1, PTS, QDPR, SPR, or PCBD1, consistent with primary BH4 deficiency.
    • The member has abnormal examination or laboratory findings indicative of renal disease, including calculated GFR <60 mL/min/1.73 m².
    • The requested medication will be used with sapropterin products, including sapropterin, Javygtor, or Kuvan, or with Palynziq (pegvaliase-pqpz).
    • The medication will not be used with a Phe-restricted diet, the prescribed dose is not FDA-approved for the member's weight, or the dose exceeds 60 mg/kg.
    • Required diagnostic, baseline laboratory, weight, treatment-response, or specialist documentation is absent.
    Sapropterin use must be in combination with dietary phenylalanine restriction
    ≥2 measurements ≥600 μmol/L
  3. Baseline phenylalanine before starting the requested medication is greater than or equal to 360 μmol/L.≥360 μmol/L
  4. Primary BH4 deficiency exclusion: Member does not have hyperphenylalaninemia due to pathogenic variants in GCH1, PTS, QDPR, SPR, or PCBD1 consistent with primary BH4 deficiency.
  5. Renal safety: Member has no abnormal physical examination or laboratory findings indicative of renal disease, including calculated GFR below 60 mL/min/1.73 m².GFR ≥60 mL/min/1.73 m²
  6. Phenylalanine-restricted diet: The medication will be used in conjunction with a phenylalanine-restricted diet.
  7. Prohibited combination therapy excluded: The medication will not be used in combination with sapropterin products or Palynziq (pegvaliase-pqpz).
  8. Weight documentation: The member’s most recent weight is documented.
  9. Dose limitation: The medication is prescribed at the appropriate FDA-approved dose based on the member’s weight and does not exceed 60 mg/kg.≤60 mg/kg
  10. Formulary sapropterin prerequisite: Member has a documented inadequate treatment response or intolerance to a formulary sapropterin product. Inadequate response is defined as blood phenylalanine of at least 360 μmol/L despite consistent use with dietary phenylalanine restriction.Blood Phe ≥360 μmol/L despite consistent use with dietary Phe restriction
  11. Neuropsychiatric response: Improvement in neuropsychiatric symptoms is documented.